Novo Nordisk, the pharmaceutical giant behind the blockbuster weight-loss injection Wegovy, has made its oral semaglutide drug, Rybelsus (often used off-label for weight management, though its primary indication is type 2 diabetes), privately available in UK pharmacies. This move significantly expands access to GLP-1 agonists for weight loss in the UK, as patients no longer require a prescription for the injectable version to access a semaglutide product.

Rybelsus offers a daily pill alternative to the weekly Wegovy injection, which has seen immense demand globally. While Rybelsus is not specifically licensed for weight loss in the UK, its active ingredient, semaglutide, is the same as Wegovy, making it a viable option for private prescriptions for weight management under a doctor's guidance. This development follows previous supply constraints on Wegovy in the UK, which limited its widespread availability.

The introduction of an oral semaglutide option in the UK market could further solidify Novo Nordisk's dominant position in the rapidly expanding weight-loss drug sector. It addresses a segment of the population preferring pills over injections and could alleviate some pressure on Wegovy supply chains by diversifying product offerings. The market will be watching how this impacts patient uptake and overall sales figures for Novo Nordisk in the region, especially given the company's strong revenue growth projections.